340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
CHA Submits Comments for Energy and Commerce Discussion Draft on Drug Shortages
CHA submitted a comment letter to the Energy and Commerce Committee to highlight pediatric needs when addressing drug shortages.
CHA Responds to Drug Shortages Request for Information
CHA submitted a response to the bicameral drug shortages request for information (RFI) to highlight pediatric health care needs.
CHA Responds to Senate 340B Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Submits Comments on 340B Proposed Rule
Children’s Hospital Association sent a comment letter to the Centers for Medicare and Medicaid Services on the 340B remedy proposed rule.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
CHA Submits Statement for the Record for Drug Shortages Hearing
Children's Hospital Association submitted a statement for a legislative hearing to highlight children’s needs when strengthening the pediatric drug supply chain.
CHA Submits Drug Shortages Hearing Statement for the Record
CHA submitted a statement for a House Energy and Commerce hearing to highlight how children’s needs must be prioritized when strengthening the pediatric drug supply chain.
Fiscal Year 2023 Omnibus Summary
This detailed summary of the FY 2023 Omnibus focuses on those provisions of most interest to children’s hospitals.
VALID Act Letter
We sent a letter to Senate HELP Committee leadership to highlight the implications of the VALID Act.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.
